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Sex EffectThe interferon regulatory factor (IRF) family of DNA-binding proteins regulates expression of interferon-
inducible genes with roles in the immune response and carcinogenesis. IRF4 is involved in the differentiation
of B and T cells and is overexpressed in B-cell malignancies as a result of c-REL (NF-κB) hyperactivation. IRF4
polymorphisms are associated with susceptibility to chronic lymphoid leukemia (CLL) and non-Hodgkin
lymphoma (NHL). We examined 13 IRF4 SNPs in 114 cases of childhood acute lymphoblastic leukemia (ALL)
and 388 newborn controls from Wales (U.K.) using TaqMan assays. IRF4 intron 4 SNP rs12203592 showed a
male-speciﬁc risk association (OR=4.4, 95% CI=1.5 to 12.6, P=0.007). Functional consequences of the CNT
substitution at this SNP were assessed by cell-based reporter assays using three different cell lines. We found
a repressive effect of the rs12203592 wildtype allele C on IRF4 promoter activity (Pb0.001) but no repression
by the variant allele in any cell line tested. Thus, homozygosity for the rs12203592 variant allele would result
in increased IRF4 expression. This increase would be compounded by high levels of NF-κB activity in males
due to the absence of estrogen. IRF4 differs from other IRFs in its anti-interferon activity which interferes
with immune surveillance. We propose that a detailed study of IRF4 can provide information on the
mechanism of the sex effect and the role of immune surveillance in childhood ALL development.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
The interferon regulatory protein (IRF) family consists of at least
nine proteins [1]. These proteins have roles in B- and T-lymphocyte
differentiation [2] and maturation as well as in regulation of
interferon-induced gene expression. One member of this family, IRF4
(also known asmultiplemyeloma 1 (MUM1) and lymphocyte-speciﬁc
interferon regulatory factor (LSIRF)) functions as a transcription factor
in lymphocyte differentiation [3, 4]. IRF4 expression is restricted to
lymphocytes of the B-cell type (pre-B, B and plasma cells) and mature
T cells [5]. IRF4 is highly expressed in multiple myeloma due to t
(6;14)×(p25;q32) translocation [6] but it is overexpressed in most B-
cell malignancies [7–9] even without a chromosomal rearrangement.
IRF4 differs from other IRFs in several ways: its expression is induced
by c-REL [10]; HTLV1 Tax protein induces leukemic transformation via
induction of IRF4 [5]; it represses IFN-induced gene expression [5], acts
as a negative regulator of TLR signaling [11] and increases telomerase
activity in B-lymphocytes [12]. Thus, while IRF family may be
considered as a major player in cancer immune surveillance, IRF4
appears to have a pro-carcinogenic activity [13].
The IRF4 gene is located at the tip of the short arm of chromosome
6 (6p25) and recent genome-wide association studies found associa-+1 609 570 1039.
).
ll rights reserved.tions between IRF4 polymorphisms and several conditions. Most
importantly, 3′ UTR SNPs rs872071 and rs12211228 are associated
with chronic lymphoid leukemia (CLL) [14] and non-Hodgkin
lymphoma risk [15], respectively. An intron 7 SNP (rs2001508) has
been found to correlate with height in subjects with type 2 diabetes
[16]. Another ﬁnding is that the intron 4 SNP rs12203592 is a marker
for population substructure in Europe and associated with eye color
and particularly with hair color [17,18]. A different SNP located in 3′
UTR of the IRF4 gene (rs9378805) is a marker for UK population
substructure [19].
Given the possible role played by IRF4 in B-cell development and
associations between its polymorphisms and hematologic malignan-
cies, we included the IRF4 gene in our childhood acute lymphoblastic
leukemia (ALL) candidate gene association studies. Here, we provide a
comprehensive analysis of IRF4 polymorphisms in a case-control
study and functional assessment of an intronic SNP association.
2. Materials and methods
2.1. Genetic association studies
2.1.1. Case and control groups
The cases analyzed were 114 childhood (≤16 years) ALL samples
consecutively diagnosed from 1988 to 1999 in SouthWales (U.K.) and
originally used to describe the male-speciﬁc HLA-DRB4 and C282Y
associations [20, 21]. Controls were 388 anonymously collected cord
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collected in two hospitals in Cardiff in 1997 and 1998 without any
selection other than they were all naturally born full-term healthy
newborns. Further characteristics of these samples were described
elsewhere [22]. We only had information on age-at-onset, sex and ALL
subtype in cases. Thus, we could only examine primary susceptibility
with age and sex effects, but not associations with clinical outcome.
The samples were used with the approval of the South Wales (U.K.)
Research Ethics Committee.
2.1.2. SNP selection and genotypings
We used the HapMap data and NCBI ENTREZ SNP to select SNPs
that will provide maximum information about the polymorphism
content about the IRF4 gene and 10 kb ﬂanking region on each side.
HapMap lists 11 haplotype tagging SNPs (htSNP) for approximately
40 kb region that includes IRF4. We genotyped all but two htSNPs
(rs4959234 and rs9391997) in the IRF4 region. We included all IRF4
SNPs that have shown associations with any condition as reported by
Johnson and O'Donnell [23], National Human Genome Research
Institute (NHGRI) Catalog of Published Genome-Wide Association
Studies [24] and HuGE Navigator [25]. The resulting 18 SNPs covered a
genomic region of 35 kb including at least 6 kb on each side of the IRF4
gene. Thus, the selected SNP list contains all SNPs in the IRF4 gene
region with known associations with a disease or trait.
Although NCBI ENTREZ SNP (build 129) lists seven coding region
SNPs (three missense ones) for IRF4, but none has double hits (i.e.,
they are not conﬁrmed polymorphisms) or frequency information
(i.e., not observed in any population sample). We still went ahead and
genotyped one of them, rs9378788 in exon 2 encoding L70L in our
control group but it did not show any polymorphism. We did not
proceed with genotyping of the other six unconﬁrmed coding region
SNPs.
We also screened other publicly available resources for selection of
functional SNPs of IRF4. The list of SNPs that show strong correlation
with gene expression levels does not contain any from the IRF4
genomic region [26]. Examination of bioinformatics resources like
SNP500Cancer, SNPs3D, FastSNP, SNPSeek and TFSEARCH did not
result in addition of any other potentially functional SNP.
Two IRF4 SNPs have been identiﬁed as geographic differentiation
markers in Europe (rs12203592) [18,27] and in the UK (rs9378805)
[19]. Since this feature of IRF4 SNPsmay cause spurious associations inTable 1
IRF4 SNPs included in the study.
SNP ID Chromosome 6 positiona Location
rs2797301c 327 111 5′ ﬂankin
rs4985288c 327 246 5′ ﬂankin
rs9405192 327 537 5′ ﬂankin
rs1033180 328 546 5′ ﬂankin
rs9378788c 338 362 exon 2
rs12203592 341 321 intron 4
rs3778607 348 799 intron 7
rs2001508 349 632 intron 7
rs1131442 352 656 exon 9-3
rs7768807c 353 246 exon 9-3
rs12211228 353 833 exon 9-3
rs1877175 355 493 exon 9-3
rs9392502 355 608 exon 9-3
rs872071 356 064 exon 9-3
rs11242865 356 954 3′ ﬂankin
rs7757906 357 741 3′ ﬂankin
rs9503644c,d 360 406 3′ ﬂankin
rs9378805 362 727 3′ ﬂankin
a NCBI Reference assembly (build 129) nucleotide positions (from telomere to centrome
b The wildtype and variant alleles in the HapMap European population as well as in the
c These SNPs could not be typed (see Results).
d Formerly rs11242867.case of cryptic population substructure, we included the top ranking
marker (lactase gene SNP rs1042712) for population substructure in
the UK identiﬁed by the Wellcome Trust Case-Control Consortium
Study [19].
All genotypings were achieved by TaqMan allelic discrimination
assays purchased from Applied Biosystems (ABI, Foster City, CA) on
Stratagene Mx3000 real-time PCR instruments using standard allelic
discrimination assay conditions. TaqMan assay numbers are provided
in Table 1. Stratagene M×3000P software was used to assign
genotypes. Safeguards against genotyping errors included inclusion
of blind duplicates (intra-plate, inter-plate), negative controls in each
assay, randomly repeated samples and examination of the data for
unexpected break of haplotypic homozygosity in homozygous
samples. We also repeated genotypings when haplotype construction
yielded rare haplotypes due to one SNP in that haplotype. At the
analytical phase, genotype distributions were examined for their
compliance with Hardy-Weinberg equilibrium proportions. The SNP
that showed an association (rs12203592) was genotyped for a second
time by a different operator.
2.1.3. Data analysis for genetic associations
Statistical analysis was performed on Stata/IC v.10 (StataCorp,
College Station, TX). We used the Stata command “genhwcci” which
tests the Hardy–Weinberg equilibrium (HWE). Statistical signiﬁcance
of associations with minor allele-positivity (dominant model) was
assessed by logistic regression (command “logistic”) and odds ratios
(OR) and their 95% conﬁdence intervals (CI) were obtained. We also
used gene-dosage effect analysis by the genotype-based trend test
(additive model) which reveals associations that depend additively
upon the minor allele. This test compares the heterozygote and then
variant homozygote frequencies with wildtype homozygote frequen-
cy, and yields genotype-speciﬁc odds ratios as well as an odds ratio
per allele for stepwise changes with the number of minor allele in the
genotype (OR per allele). Using the wild type genotype as reference,
independence of associations was assessed by multivariable logistic
regression. All P values presented are two-sided. Linkage disequilib-
rium (LD) analysis, LD plot generation and haplotype construction
were achieved on Haploview v4.0 (http://www.broad.mit.edu/
haploview/haploview). Haploview also provided statistical assess-
ment of allele frequency comparisons between cases and controls
(corresponding to multiplicative model).Nucleotide changeb ABI
TaqMan kit no
g CNG C__27071526_10
g GNT C__27957646_10
g GNA C__27071545_10
g CNT C___1576195_10
not polymorphic (PCR-RFLP)
CNT C__31918199_10
ANG C__27499861_10
ANC C___1576163_20
′UTR GNA C___1576159_20
′UTR TNC C___1576158_10
′UTR GNC C__31918237_10
′UTR GNA C___1576157_10
′UTR CNG C___1576155_10
′UTR ANG C___8770093_10
g CNT C___1576153_10
g GNA C__29334722_20
g GNA C__30106657_20
g ANC C__30340659_10
re). The IRF4 gene lies between 336 760 and 356 193.
current study control group.
294 T.N. Do et al. / Biochimica et Biophysica Acta 1802 (2010) 292–3003. Functional assessment of the intronic risk marker
For further details of the methods described below, see the
Supplementary Material.
3.1. Cells and reagents
The EBV-positive human Burkitt lymphoma B cells (Raji) (#CCL-
86), the human adrenal NCI-H295R cells (#CRL-2128), and the human
embryonic kidney HEK-293T (#CRL-1573) were purchased from the
American Type Culture Collection (ATCC, Manassas, VA, USA).
3.2. Ampliﬁcation of IRF4 promoter and IRF4 intron 4 fragments
from genomic DNA
The PCRwas used to amplify IRF4 2.4 kb promoter fragment and its
full 1.2 kb intron 4 from two different cell lines (PGF (IHWG #9318)
and LWAGS (IHWG #79)). Cell line PGF is wildtype homozygous (CC)
for our SNP of interest (rs12203592) in intron 4 and cell line LWAGS is
homozygous for the variant allele (TT).
Four IRF4 intron 4 fragments from the two cell lines were obtained
by PCR. All four fragments from each cell line were identical except at
their terminal sequences where unique endonuclease restriction sites
were introduced. These unique restriction sites facilitated the sub-
cloning of intron 4 in the sense and antisense direction both proximal
and distal to the luciferase reporter gene.
3.3. Construction of expression vectors
All of Taq polymerase-ampliﬁed PCR products (IRF4 promoter and
intron 4) were ﬁrst subcloned into the pCR®2.1-TOPO vector (Invitro-
gen) and transformed to TOP10 competent cells (Invitrogen). At this
step, all PCR ampliﬁed products were fully sequenced in both directions
and all sequences are identical to the sequences published in GenBank.
The IRF4 promoters were liberated from TOPO vector using XhoI
and HindIII enzymes. Intron 4 fragments were released from TOPO
vectors using the restriction enzymes. KpNI and XhoI for intron 4
fragments to be cloned 5′ immediately upstream of IRF4 promoter
and SalI and BamHI for those to be downstream of the luciferase gene.
The IRF4 promoters were subcloned into the XhoI- and-HindIII-
digested pGL4.10[luc2] luciferase vector (Promega). Since the sequences
of both IRF4 promoters from two different cell lines were identical and
their transcriptional activities were conﬁrmed to be similar in all three
cell lines (see Results), IRF4 promoter from the PGF cell line was used
for further experiments with different IRF4 intron 4 fragments.
3.4. Site-directed mutagenesis
Construct C_D(+) was used to change the wild type allele C in
intron 4 to the variant allele T (C_D(+)CtoT) using a Change-IT
multiple-mutation site-directed mutagenesis kit (USB, Cleveland,
Ohio, USA) with phosphorylated primers ordered from Integrated
DNA Technology (IDT, Coralville, IA, USA). The ﬁdelity of all
constructions was veriﬁed by sequencing in both directions, and
after that, they were puriﬁed using Qiagen columns.
3.5. Sequencing
Sequencing analysis was performed with the CEQ dye terminator
cycle sequencing kit on the CEQ8000 Genetic Analysis System
(Beckman Coulter, Fullerton, CA, USA).
3.6. Transient transfection and luciferase assay
For Raji cells, transfection was performed with Nucleofector™
Technology (Lonza, Walkersville, MD, USA), with 2×106 logarithmi-cally growing cells nucleofected using a Cell Line Nucleofector™ Kit V,
programM-13 and 2 μg of plasmid in eachwell of a 12-well plate. NCI-
H295R and HEK-293T cells were plated at a density of 106 or 105 cells/
well in each well of a 12-well plate, respectively, and incubated for
24 h before transfection using the Lipofectamine™2000 Transfection
Reagent (Invitrogen, Carlsbad, CA, USA). The relative light units at
48 h after incubation were similar to that of the 24 h; therefore, 24
h was chosen for all experiments. Cells were transfected with either
luciferase vector driven by IRF4 promoter or control plasmids
(pGL4.10[luc2] and pGL4.13[luc2/SV40]). Co-transfection of the Re-
nilla luciferase reporter pGL4.73[hRenilla/SV40] (Promega) was used
as a control for transfection efﬁciency in a 25:1 molar ratio (ﬁreﬂy:
renilla). Where necessary, pcDNA3.1[cmvP] was used to make up the
total amount of DNA in the transfection. Cells were harvested and the
luciferase activity was measured in cellular extracts using the Dual-
Glo Luciferase Reporter Assay System (Promega, Madison, WI, USA).
The ﬁreﬂy luciferase activity was normalized by the Renilla luciferase,
and the result was expressed as relative luciferase activity. All
constructs were transfected in triplicates, and the results represent
the mean of three independent experiments±SE. All statistical
analyses were done using non-parametric Mann–Whitney test.
3.7. Oligonucleotide synthesis for DNA-protein binding assay
In silico analyses suggested the binding of the transcription factor
AP-2α to the SNP that was found to be the risk marker (see Results),
we designed a DNA-protein binding assay to experimentally test this
prediction.
3.8. DNA-protein binding assay
HEK-293T cells at 80–90% conﬂuent were harvested, and cyto-
plasma- and nuclear-extracts were prepared using the ProteoJet™
Cytoplasmic and Nuclear Protein Extraction Kit (Fermentas, Ger-
many). NanoDropND-1000 Spectrophotometer (Nano-Drop Technol-
ogies, Wilmington, DE, USA) was used to estimate protein
concentration. DNA-protein binding assays were performed using a
streptavidin–agarose bead pulldown assay [28]. Relative intensity of
Western blot bands was quantiﬁed using the GS-800 calibrated
densitometer (BioRad, CA, USA).
3.9. Western blotting
The eluted proteins were subjected to a 4–12% gradient Bis-Tris gel
(BioRad, Hercules, CA, USA) by electrophoresis and transferred
electrophoretically to a polyvinylidene diﬂuoride membrane (Milli-
pore Corp., Bedford, MA, USA). The membrane was then blocked in a
blocking solution (5% nonfat dry milk/Tris-buffered solution) and
then incubated with primary antibody overnight. For both AP-2α and
Tst-1 (Oct-6) detection, a 1:1000 dilution of an anti-AP-2α polyclonal
antibody (sc-8975) or an anti-Oct-6 (sc-28593) (Santa Cruz Biotech-
nology Inc., Santa Cruz, CA) were used. The unbound primary
antibody was removed by washing the membrane with 0.1 %
Tween/Tris-buffered solution, followed by incubation with horserad-
ish peroxidase-conjugated secondary antibody diluted 1:3000 in 0.5%
nonfat dry milk/Tween/Tris-buffered solution. Proteins were visual-
ized using enhanced chemiluminescence reagent (Amersham Phar-
macia Biotech) and X-ray ﬁlm.
4. Results
4.1. Cases and controls
The case-control group consisted of 114 childhood (≤16 years)
ALL cases (62 males and 52 females) and 388 newborn controls (201
girls and 187 boys) collected at overlapping time periods from the
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association studies before [20,21], and more recently, TP53 [29] and
HSPA1B [22] association were also reported. Of the 114 cases, 93
(81.6%) had B-cell precursor ALL, 10 (8.8%) T-cell ALL, 6 (5.3) B-cell
ALL, 4 (3.5%) null and 1 case had unclassiﬁed ALL. While the overall
male-to-female ratio was 1.19, it was 2.33 in the T-ALL group and the
average age was also higher in the T-ALL group (95 vs. 59 months).
The overall mean age of onset was 62.4 months (median=51,
range=1 to 180). In the most common subtype B-cell precursor ALL
(n=93), the mean age was 57.8 months (median=48, range=1 to
180) and in the T-ALL subgroup (n=10), themean agewas 95months
(median=96, range=46 to 156).
4.2. Genotyping results
Four of the SNPs (rs2797301, rs4985288, rs7768807, rs9503644)
listed in Table 1 could not be genotyped because of TaqMan assay
failure. As mentioned in theMaterials andmethods, one coding region
SNP (rs9378788) listed in the NCBI ENTREZ SNP was not polymorphic
and not genotyped. Thus, out of the 18 SNPs selected for genotyping,
13 of them were genotyped in cases and controls. Distributions of
genotypes at all these SNPs were in Hardy–Weinberg equilibrium
with the exception of rs9378805 that showed slight deviation in the
whole of control group (P=0.01). In the analysis after stratiﬁcation by
sex, the deviationwas exclusive tomale newborns (P=0.008 inmales
and P=0.18 in females) suggesting possible involvement in prenatal
selection rather than an explanation concerning whole of the control
group. The genotype distribution of the lactase gene SNP rs1042712
genotyped as amarker for geographic differentiation in the UK did not
violate HWE, and did not show any statistically signiﬁcant association
in case-control comparison, thus ruling out detectable population
substructure.
4.3. Linkage disequilibrium analysis and haplotype construction
Using the default options of Haploview, the only strong (r2N0.80)
LD was between the two 3′ end SNPs rs1877175 and rs11242865Table 2
Univariable analysis of associations between 13 IRF4 SNPs and childhood ALLa,b
SNP Wildtype Heterozygote
rs9405192 1.0 (referent)
(0.531 vs. 0.521) b
1.04 (0.66 to 1.66
(0.418 vs. 0.393)
rs1033180 1.0 (referent)
(0.906 vs. 0.875)
0.69 (0.32 to 1.45
(0.085 vs. 0.012)
rs12203592 1.0 (referent)
(0.606 vs. 0.654)
0.98 (0.60 to 1.61
(0.269 vs. 0.296)
rs3778607 1.0 (referent)
(0.353 vs. 0.326)
0.81 (0.49 to 1.34
(0.422 vs. 0.480)
rs2001508 1.0 (referent)
(0.472 vs. 0.503)
1.12 (0.71 to 1.77
(0.426 vs. 0.402)
rs1131442 1.0 (referent)
(0.480 vs. 0.513)
1.11 (0.70 to 1.75
(0.430 vs. 0.415)
rs12211228 1.0 (referent)
(0.750 vs. 0.742)
0.93 (0.55 to 1.74
(0.220 vs. 0.235)
rs1877175 1.0 (referent)
(0.686 vs. 0.645)
0.88 (0.54 to 1.42
(0.286 vs. 0.306)
rs9392502 1.0 (referent)
(0.694 vs. 0.707)
0.99 (0.60 to 1.61
(0.259 vs. 0.268)
rs872071 1.0 (referent)
(0.340 vs. 0.293)
0.79 (0.48 to 1.30
(0.453 vs. 0.493)
rs11242865 1.0 (referent)
(0.705 vs. 0.666)
0.95 (0.59 to 1.54
(0.295 vs. 0.293)
rs7757906 1.0 (referent)
(0.621 vs. 0.559)
0.77 (0.49 to 1.24
(0.330 vs. 0.384)
rs9378805 1.0 (referent)
(0.273 vs. 0.312)
1.16 (0.69 to 1.94
(0.431 vs. 0.431)
aOdds ratios and 95% conﬁdence intervals using the wildtype homozygous genotype as refer
model) given is per allele.(r2N0.91; D'=0.96). Sex-speciﬁc LD patterns did not show any
difference.
4.4. Univariable data analysis
In allele frequency comparisons, there was no statistically
signiﬁcant change between cases and controls in the overall group.
The largest difference was noted for the intron 4 SNP rs12203592
(0.255 vs. 0.197, P=0.07). The difference was larger in males-only
analysis (0.277 vs. 0.169, P=0.01) with no difference in female cases
and controls (0.228 vs. 0.222, P=0.90).
In Table 2, we present the results of additive gene-dosage model
statistics for the overall group. Again, the largest difference was
observed for intron 4 SNP with the homozygosity rates between cases
and controls showing a signiﬁcant difference (in reference to wildtype
genotype, P=0.009). These ﬁndings prompted us to perform a
detailed analysis of the association of rs12203592 (alternative name:
NT_034880.3:g.336321CNT) with childhood ALL. Sex-speciﬁc analysis
conﬁrmed that the association was exclusive to males. Homozygosity
for the variant allele T conferred an increased risk for childhood ALL in
males (in reference to thewildtype genotype, OR=4.86, 95% CI=1.64
to 14.4; P=0.004). In females, the same association did not reach
statistical signiﬁcance (P=0.42). As the data presented in Table 2
suggested, the recessivemodelwas the bestﬁt to themale-speciﬁc risk
association of rs12203592 with childhood ALL. The homozygous
genotype increased the risk in males very strongly (in reference to the
other genotypes, OR=4.36, 95% CI=1.51 to 12.6, P=0.007) but not in
females, although there was a non-signiﬁcant increase in odds ratio
(OR=1.79, 95% CI=0.60 to 5.28, P=0.29). All r2 values for LD
between these SNPs and the other 12 IRF4 SNPs wereb0.10. Thus, this
association was not confounded by any of the IRF4 SNPs examined in
the present study.
Themale-speciﬁc riskmarker was present in 3 of 7male T-ALL cases
and 5 of 48male B-cell precursor ALL (42.9% vs. 10.4%) but the numbers
were too small for assessment of the statistical signiﬁcance. Likewise the
average age of onset in males with the risk genotype group was
77 months compared with 70 months in the remainder of male cases.Variant homozygote P (additive model)c
) a
b
0.58 (0.22 to 1.57) a
(0.051 vs. 0.086) b
0.89 (0.63 to 1.28)
P=0.54
) 1.83 (0.16 to 20.4)
(0.005 vs. 0.009)
0.80 (0.41 to 1.54)
P=0.50
) 2.71 (1.28 to 5.75)
(0.125 vs. 0.050)
1.37 (0.98 to 1.91)
P=0.07
) 1.07 (0.59 to 1.96)
(0.225 vs. 0.194)
1.01 (0.74 to 1.37)
P=0.96
) 1.12 (0.53 to 2.36)
(0.102 vs. 0.096)
1.08 (0.78 to 1.49)
P=0.63
) 1.32 (0.59 to 2.97)
(0.090 vs. 0.073)
1.13 (0.80 to 1.59)
P=0.48
) 1.31 (0.35 to 4.95)
(0.030 vs. 0.023)
1.00 (0.64 to 1.55)
P=1.00
) 0.55 (0.16 to 1.92)
(0.029 vs. 0.049)
0.82 (0.55 to 1.22)
P=0.33
) 1.93 (0.63 to 5.94)
(0.046 vs. 0.024)
1.13 (0.76 to 1.68)
P=0.55
) 0.84 (0.46 to 1.53)
(0.208 vs. 0.214)
0.90 (0.66 to 1.22)
P=0.50
) 0.11 (0.01 to 1.79)
(0.000 vs. 0.041)
0.75 (0.49 to 1.15)
P=0.19
) 0.77 (0.28 to 2.12)
(0.049 vs. 0.057)
0.82 (0.56 to 1.19)
P=0.30
) 1.29 (0.73 to 2.28)
(0.291 vs. 0.258)
1.14 (0.85 to 1.51)
P=0.38
ence and bFrequencies in cases (n=114) and controls (n=388); cOdds ratio (additive
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associated SNP rs12211228 [15] and the 3′UTR SNP rs9378805 [16]
associated with height in subjects with T2D in detail. None of these
SNPs showed a statistically signiﬁcant association with childhood ALL
in either sex or in the overall sample. There was no LD between any of
these SNPs and the intron 4 SNP rs12203592.
4.5. Multivariable analysis
In the presence of other male-speciﬁc genetic associations with
immunologic functions in the same case-control group [20,22], we
considered the independence of all these associations. In a multivar-
iable model, the DRB4, HSPA1B rs1061581 and IRF4 rs12203592
homozygosity all retained their statistical signiﬁcance for their
associations in males. In this model, the adjusted OR for the IRF4
SNP was 4.26 (95% CI=1.33 to 13.6, P=0.01) using the wildtype
genotype as reference.
4.6. Promoter reporter assays
In order to study the functional role of IRF4 intron 4 SNP in the
regulation of IRF4 expression level, two IRF4 promoter (IRF4P)
fragments (2.4 kb) were ampliﬁed from two different cell lines. The
sequences of both homozygous (C)IRF4P and (T)IRF4P were fully
sequenced in both directions to check for any promoter SNP that
might be in LD with the studied SNP rs12203592 CNT in intron 4.
There are seven known SNPs in this 2.4-kb IRF4 promoter according to
the published sequence in the Ensembl database; however, both of
our IRF4 promoters possess all the wild type alleles for these seven
SNPs. We did not detect any new polymorphism. Functionally, the
luciferase activities from these two IRF4 promoters were determined
to be very similar in all three cell lines used in this study: Raji (Fig. 1),
HEK-293T, and NCI-H295R (not shown).
Raji is a suspension cell line and therefore was transfected using
Cell Line Nucleofector™ Kit V from Amaxa. The transfection efﬁciency
determined by FACS analysis and EGFP plasmid was around 70% (data
not shown). An included positive control pGL4.13[luc2/SV40] in every
experiment always yielded a very high luciferase reading (∼600
units), whereas that for IRF4 promoter is only in the range of 5 to 9
units. The consistent data of the positive control suggested that the
low IRF4 promoter's transcriptional activity in Raji cells was not due toFig. 1. IRF4 intron 4 with wild type allele C at SNP rs12203592 represses IRF4 promoter activ
Both work in an orientation- and position-independent manner. The full 1.2-kb fragment of
rs12203592) was subcloned into the luciferase-reporter plasmid driven by a 2.4-kb IRF4 prom
LUC is used as a reporter gene whose mRNA is stabilized by a polyadenylation/splice signal
and with the internal control plasmid pGL4.13[hRenilla/SV40] and then assayed for both ﬁre
ﬁreﬂy luciferase values were standardized to Renilla luciferase values. The results are from t
between intron 4 with the variant allele T and intron 4 with the wild type allele C; #compalow transfection efﬁciency. The same amount of plasmid DNA was
used to transfect the other two adherent cell lines (HEK-293T and
NCI-H295R); however, in these two cell lines the luciferase reading of
IRF4 promoters were at least as high as that of the positive control
pGL4.13[luc2/SV40]. For all three cell lines, data was collected at both
24 and 48 h, the luciferase readings of both ﬁreﬂy and Renilla were
higher in 48 h; however the normalized relative units (ﬁreﬂy/renilla)
were similar for both 24 and 48 data points. Therefore, 24 h was
chosen for analysis in all experiments.
Next, to determine whether the IRF4 intron 4 has any transcrip-
tional regulatory function, ﬁreﬂy luciferase reporter gene vectorswere
generatedwith IRF4 promoter (2.4 kb) in the presence of IRF4 intron 4.
Recombinant plasmids with this IRF4 intron 4 fragment inserted in
both orientations (+ and −), both upstream (C_U(+) and C_U(−))
and downstream (C_D(+) and C_D(−)) of the IRF4 promoter, as well
as the parent plasmids with just IRF4 promoter (IRF4P), were
independently nucleofected into a human Burkitt lymphoma B
lymphocyte cell line called Raji and assayed for luciferase activity at
5 and 24 h later. The data from both time points were similar in which
this intronic 4 fragment repressed expression by the IRF4 promoter
more than 2 folds (Fig. 1). Intron 4 fragment downstream of IRF4
promoter had the ability to repress the transcriptional activity more
than when it was placed upstream of the promoter. The results
demonstrated that the IRF4 intron 4 contains a repressor element that
functions in an orientation- and position-independent fashion.
Our goal was to determine if a change from C to T at SNP
rs12203592 in this IRF4 intron 4 will change the repressive effect of
IRF4 intron 4 upon IRF4 promoter activity. In order to test this, we
generated four additional plasmids with IRF4 promoter and IRF4
intron 4 with homozygous genotype for the variant allele T : T_U(+),
T_U(−), T_D(+) and T_D(−).
Intron 4 with the variant allele T had less repressive effect than the
wild type allele C especially when it was placed at the downstream
position (Fig. 1). To determine if this effect was due speciﬁcally from a
change of C to T at this SNP in intron 4, the construct containing intron
4 with the wild type allele C downstream in sense direction (C_D(+))
was mutated to T using PCR. The data showed that the mutated
plasmid CD(+)_CtoT also had less repressive effect than that of its
partner CD(+). These results suggested that the repressive effect of
intron 4 might result mostly due to a transcription factor binding to
the wild type sequence with allele C.ity while IRF4 intron 4 with variant allele T signiﬁcantly alleviates this repressive effect.
intron 4 of the human IRF4 gene (contains either a wild type C or variant allele T at SNP
oter (the big black arrow right before luciferase gene (LUC)). In all of the constructs, the
from the simian virus 40 (Poly A). Raji cells were co-nucleofected with these constructs
ﬂy and Renilla luciferases after 24 h. To adjust for differences in transfection efﬁciencies,
hree independent experiments. The error bars represent standard errors. ⁎Comparison
rison between CD(+)CtoT with TD(+).
Fig. 2. IRF4 wild type intron 4 represses IRF4 promoter activity while intron 4 with the
variant allele T alleviates the repressive effect also in twomore cell lines: (A) HEK-293T
and (B) NCI-H295R. Cells were co-transfected with the constructs described in Fig. 1
and the internal control plasmid pGL413[hRenilla/SV40]; then assayed for both ﬁreﬂy
and Renilla luciferases after 24 h. To adjust for differences in transfection efﬁciencies,
ﬁreﬂy luciferase values were standardized to Renilla luciferase values to give the
relative light unit (RLU). The results are from three to four independent experiments.
The error bars represent standard errors. ⁎Pb0.0001.
Fig. 3. Representative immunoblots showing AP-2α and Tst-1 detection in (column 1)
HEK-293T nuclear extract, (column 2) nuclear extract incubated with 5 qqpmol of
biotin-labeled DNA oligonucleotides known to bind to AP-2α, (column 3 and 4)
50 pmol of the biotin-labeled DNA oligonucleotides spanning the IRF4 intron 4 SNP
alleles C and T. Nuclear extract prepared from HEK-293T cells were incubated with the
biotin-labeled DNA oligonucleotides and streptavidin–agarose resins for 1 h and
proteins in the complex analyzed by Western blots. The western blot was ﬁrst probed
with anti-AP-2α, then stripped and reprobed with anti-Tst-1 (Oct-6) antibody. The bar
graph shows mean±SE of four experiments.
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themalignant cells. Using qPCRwith TaqManexpression assay for IRF4
and 18sRNA, we conﬁrmed the presence of IRF4 mRNA at a similar
level of that in Raji cells in the two adherent cell lines available to us:
the human embryonic kidney 293T (HEK-293T) transformed with
adenovirus 5 DNA and the carcinoma human adrenocortical cell line
(NCI-H295R) (data not shown). The transcriptional activity of the
2.4 kb IRF4 promoter driving the luciferase reporter gene was very
strong in both HEK-293 and NCI-H295R as compared to that of a
positive luciferase vector driven by a constitutively expressed
promoter SV40 (pGL4.13[luc2/SV40]. Since the IRF4 promoter func-
tions strongly in these two cell lines, we were also interested to
conﬁrm the differential effect of IRF4 intron 4 SNP rs12203592.
In both HEK-293T and NCI-H295R cells, only four key plasmids
were tested along with the negative and positive controls (pGL4.10
[luc2] and pGL4.13[luc2/SV40]) (Fig. 2). The data consistently showed
the same pattern as that seen in Raji cells. Intron 4 with the wild type
allele C downstream of IRF4 promoter C_D(+) repressed the
transcriptional activity of IRF4 promoter about 2 fold and the effect
is greatly alleviated with intron 4 having the variant T allele (T_D(+))
orwhen the allele Cwasmutated to the variant allele T (C_D(+)CtoT).
4.7. Streptavidin–agarose pulldown assay
Two bioinformatics web tools were used to predict transcription
factor binding sites in IRF4 intron 4 sequences spanning the SNP
rs12203592 CNT. FastSNP predicted that the SNP lies in a binding site
for NF-κB or Tst-1 but allelic variation does not change binding afﬁnity.
The transcription element search system (TESS) predicted that
transcription factor AP-2α binds to the DNA sequence when the SNP
has allele C but not to the variant allele containing sequence. Out of the
three cell lines used for reporter gene assay in this study,HEK-293T cell
line was used as a representative candidate for the examination ofdifferential binding of IRF4 intron 4 SNP ologionucleotides to AP-2α.
Usingwestern blotting, wewere able to detect a high level of Tst-1 and
AP-2α in both the cytosol and nuclear extract of HEK-293T cells;
however, both p65 and p50 subunits of NF-κB were detected only in
the cytosol and not in the nuclear extract (data not shown). The
original reporter gene assay was performed in an unstimulated cell
system and since NF-kB binding is not predicted to vary by sequence
variation, we did not repeat western blotting using stimulated cells.
To examine the prediction that allelic variation at the SNP site
alters AP-2α binding afﬁnity, we chose a streptavidin–agarose pull-
down assay over the electrophoretic mobility shift assay (EMSA) as it
does not require radiolabeled probes. This method involves incuba-
tion of nuclear extract protein with 5′-biotinylated double-stranded
DNA probes and streptavidin–agarose resins [28]. The protein-DNA
complex is pulled down by centrifugation, and proteins in the
complex are dissociated and analyzed by Western blotting.
We used two 25-bp biotinylated-double-stranded DNA
sequences spanning the IRF4 SNP rs12203592 with either the wild
type allele C or the variant allele T as the probes to assess their
relative binding afﬁnities to transcription factor AP-2α in the
nuclear extract of HEK-293T by the streptavidin–agarose resins
pulldown assay. Positive control oligonucleotides known to bind to
AP-2α were also included in every experiment. Results from four
independent experiments consistently showed that oligonucleotides
with the wild type allele C were able to bind to AP-2α about 60%
stronger than that with the variant allele (Fig. 3). A negative control
including everything except oligonucleotides did not pull down any
AP-2α protein (data not shown).
We then stripped the same blot to and reprobed with Tst-1(Oct-6)
antibody since FastSNP predicted binding of Tst-1 to the same
sequence without speciﬁcity to the allelic variation. We did not try
the same with NF-kB because it was not detectable in the nuclear
extract of the unstimulated cell line used. Both oligonucleotides
spanning the SNP (with alleles C or T) were able to pull down similar
amounts of Tst-1 protein. The positive control oligonucleotide for AP-
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protein detected in both lanes conﬁrmed that the differences seen in
AP-2α bindings to C or T carrying oligonucleotides were due to
differential binding afﬁnities and not to technical reasons.
5. Discussion
This comprehensive study of IRF4 polymorphisms identiﬁed a
male-speciﬁc risk association between childhood ALL and an intronic
SNP and demonstrated its effect on gene transcription in vitro. While
rs12203592 was associated with childhood ALL, other IRF4 SNPs
associated with CLL (rs872071) or NHL (rs12211228) did not show
any association and there was no LD between the intron 4 SNP and the
other SNPs associated with other hematopoietic cancers. Bioinfor-
matics analysis on SNPSeek shows that the ALL- and CLL-associated
SNPs are located in a regulatory-potential region from 7-species
alignment and the NHL-associated SNP is in a human-mouse-rat
conserved region. Of these three SNPs, only rs12203592 has been
examined for its functional effect experimentally (the present study).
The intronic SNP rs12203592 has an interesting feature. The
examination of the HapMap data showed that the variant allele only
occurs in the European population sample with no polymorphism
detected in African and Asian samples. The HapMap European
frequencies are 0.167 for the variant allele and 0.033 for variant allele
homozygosity. These are similar to the frequencies in the control
group of the present study (0.197 and 0.050, respectively). Even
within Europe, the allele frequencies show regional variation between
the Irish population and Northern/Eastern/Central European popula-
tions [18, 27]. This follows the ﬁnding that the variant allele of this SNP
is enriched in people with black hair, fair skin and blue eyes with poor
tanning ability. We did not have hair color data to exclude a
confounding of the observed association by differential representation
of individuals with different hair colors in cases and controls but this is
an unlikely explanation for the observed association.
Besides rs12203592 being a geographic differentiation marker in
Europe, another IRF4 SNP rs9378805 has been identiﬁed as a one of
the 13 similar markers speciﬁcally for the UK population [19]. The 3′
UTR SNP rs9378805 ranks fourth as an informative marker among the
UK-speciﬁc markers [19]. To rule out a spurious association possibility
due to cryptic population substructure in our case-control sample, we
also examined the top ranking UK-speciﬁc marker (LCT rs1042712).
Neither SNP showed a frequency difference between cases and
controls or between sexes to suggest population stratiﬁcation that
may account for the observed association. Statistical adjustments for
these two SNPs did not cause an appreciable change in the male-
speciﬁc association of the intron 4 SNP either. Given the fact that the
detailed principal component analysis of the UK population sample by
the Wellcome Trust Case-Control Consortium concluded that within
the UK, the population structure is very weak, we are conﬁdent that
the association is not a spurious ﬁnding. The sex effect and association
with a homozygous genotype rather than variant allele positivity also
make population stratiﬁcation an unlikely alternative explanation.
Like any statistical association, the rs12203592 association
required an independent replication or functional conﬁrmation. We
ﬁrst examined bioinformatics resources for predicted functions.
FastSNP/TFSEARCH analysis suggested an intronic enhancer function
for rs12203592 due to its location in transcription factors NF-κB and
Tst-I binding sites. However, the SNP does not change the binding
characteristics of these transcription factors in silico. Having elimi-
nated LD and identiﬁed the rs12203592 association as the primary
association, we went ahead and examined the functional conse-
quences of nucleotide substitution on gene transcription by in vitro
assays. Using three cell lines and natural sequence variants as well as
site-directed mutagenesis variants, we showed a repressive effect of
intron 4 with the wildtype allele C on IRF4 promoter activity
(Pb0.001) but no repression by the variant allele T. Thus, homozy-gosity for the rs12203592 variant allele would result in increased IRF4
expression if IRF4 expression is induced.
The results from our in vitro experiments conﬁrmed the predic-
tions of in silico analyses and suggested a role of AP-2α in regulating
the transcriptional activity of IRF4 gene by differentially binding to
IRF4 rs12203592 alleles. We used the streptavidin–agarose pulldown
assay and determined that the wild type sequence of IRF4 intron 4
binds more than 2 folds stronger to the transcription factor AP-2α
than that with the variant allele T (Fig. 3). The reporter gene assay
showed that the wild type intron 4 has a repressive effect on the
transcriptional activity of IRF4 promoter and the repressive effect was
signiﬁcantly alleviated when the nucleotide C at the rs12203592
position is replaced by the variant allele T. Based on the observations
from this study, we propose that AP-2α may be the mediator of the
repressive effect on the IRF4 gene as it does with other genes in other
cancers [30,31]. Although AP-2 family is generally considered to be an
activator of transcription, recent studies have also shown that AP-2α
may negatively regulate the transcription of certain genes in cancer
cells [30,31].
IRF4 is a distinct member of the IRF family of transcription factors.
It differs from other IRFs in several ways including its repressive effect
on IFN-induced gene expression [5, 32] and induction by proliferative
stimuli [5,33]. These and other unique effects [5,10-12,34] culminate
into an oncogenic activity [13]. Most B-cell malignancies have
increased IRF4 expression [7–9] presumably required to maintain
their malignant phenotype. Our ﬁnding of a risk association with an
intronic SNP that would facilitate increased IRF4 expression in
childhood ALL, which is predominantly a B-cell origin malignancy, is
therefore biologically plausible.
The sex effect we observed in the IRF4 association is not
unexpected given the previous observations of sex-speciﬁc associa-
tions in childhood ALL [20-22,29,35-37]. The identiﬁcation of the
mechanism of themale-speciﬁcity of this risk association with an IRF4
polymorphism requires detailed studies but a working hypothesis can
be put forward as follows: IRF4 overexpression in malignancies is due
to hyperactivation of c-REL which is a common occurrence [10, 38]
including hematopoietic cancers [39,40], speciﬁcally in childhood ALL
[41]. Experimentally, induction of IRF4 expression by v-Rel facilitates
transformation of ﬁbroblasts [34]. Overexpression of REL, which is
accompanied by increased expression of IRF4, increases the oncogenic
properties of the human B-cell lymphoma BJAB cell line [39]. The REL
gene encodes c-Rel, a transcription factor that is a member of the Rel/
NF-κB family. Since the effects of NF-κB on its downstream target
genes are suppressed by estrogens [42], overexpression of IRF4 in
cancer is expected to be stronger in males. This may be the basis of the
male-speciﬁcity of the rs12203592 association.
There are only limited examples of mechanisms of sex effects in
cancer and no functional mechanism is shown for the sex-speciﬁcity
of any genetic association. Our datamay hint the ﬁrst suchmechanism
if followed up and conﬁrmed by signal transduction studies of NF-kB
pathway and its interaction with IRF4. Two other knownmechanisms
of the sex effect in cancer predisposition in thyroid cancer [43] and
liver cancer [44,45] both involve sex hormones. Thyroid follicular
cancer is one of those cancers that are more frequent in females. It has
been suggested thatmalesmay be protected due to androgen receptor
expression in thyroid follicular cells through which androgens reduce
proliferation of follicular cells. Lacking this effect, females are at
higher risk of developing thyroid follicular cancer. In the case of liver
cancer, it has been shown that estrogens inhibit IL-6 secretion which
is a key mediator of liver cancer development and females are
protected owing to estrogen effect.
We recently reported another sex-speciﬁc association of MDM2
SNP (rs2279744, SNP309) with age-at-onset in the same case-control
group [29]. The association with earlier age-at-onset was observed
only in females, as has been noted also in adult cancers. This effect is
attributed to the effect of estrogen [29]. The MDM2 association with
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action in childhood ALL. However, there is only negligible estrogen
activity in childhood, and raises the possibility of mediation of fetal
programming of childhood ALL susceptibility by sex hormones. Fetal
programming of susceptibility to adult diseases has been shown in
several diseases [46] but it has not been considered for childhood
leukemia.
The present study provided yet another example of a functional
intronic polymorphism. It has already been recognized that intronic
SNPs should not be dismissed as non-functional polymorphisms in
genetic association studies [47-49]. Besides, the present study also
exempliﬁed the importance of taking sex into account in analysis.
Unfortunately, most study results are reported with adjustment for
sex but that analysis only adjusts for confounding. To uncover a sex
effect or effect modiﬁcation by sex, either stratiﬁed analysis or
examination of interaction is required. Finally, we chose to examine
the functionality of the associated SNP to validate the statistical
association. This way, we avoided further statistical manipulations
(such as the conservative Bonferonni correction) to increase the
conﬁdence levels in our statistical association. No statistical manip-
ulation can substitute experimental data for the functionality of a SNP
that shows an association. Overall our results suggested a mechanism
for the greater predilection of males to childhood ALL and perhaps to
other cancers. The hypothesis that we generated in the present study
which proposes that REL activation induces the oncogenic IRF4
expression more strongly in males and especially if they are
homozygous for the intron 4 SNP variant allele is testable in any
cancer. If conﬁrmed, this mechanism can be targeted pharmacolog-
ically as already suggested [38].
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